We are live on ! Find out more
FLGT icon

Fulgent Genetics

173 hedge funds and large institutions have $299M invested in Fulgent Genetics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,961% more call options, than puts

Call options by funds: $40.6M | Put options by funds: $670K

21% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 48

1.24% more ownership

Funds ownership: 49.73%50.97% (+1.2%)

4% less funds holding

Funds holding: 180173 (-7)

7% less capital invested

Capital invested by funds: $322M → $299M (-$23M)

14% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 35

Holders
173
Holders Change
-7
Holders Change %
-3.89%
% of All Funds
2.5%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
30
Increased
58
Reduced
48
Closed
35
Calls
$40.6M
Puts
$670K
Net Calls
+$39.9M
Net Calls Change
-$5.03M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$76.9M +$11.4K +547 +0%
Vanguard Group
2
Vanguard Group
Pennsylvania
$28.2M +$229K +10,977 +0.8%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$23.9M -$2.69M -128,791 -10%
Millennium Management
4
Millennium Management
New York
$18.8M +$5.11M +244,981 +34%
PWAM
5
Park West Asset Management
California
$16.4M +$2.16M +103,586 +14%
State Street
6
State Street
Massachusetts
$15.4M -$873K -41,800 -5%
DSCM
7
Divisadero Street Capital Management
Florida
$9.91M +$3.34M +160,212 +46%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$9.61M +$358K +17,168 +4%
Morgan Stanley
9
Morgan Stanley
New York
$7.24M +$3.11M +148,885 +68%
Ameriprise
10
Ameriprise
Minnesota
$6.96M -$113K -5,410 -2%
Charles Schwab
11
Charles Schwab
California
$5.28M -$536K -25,684 -9%
Northern Trust
12
Northern Trust
Illinois
$4.27M -$73K -3,497 -2%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$3.95M +$1.15M +55,020 +38%
Citadel Advisors
14
Citadel Advisors
Florida
$3.65M +$1.54M +73,796 +66%
Invesco
15
Invesco
Georgia
$3.27M -$79.6K -3,811 -2%
JP Morgan Chase
16
JP Morgan Chase
New York
$3.11M -$1.27K -61 -0%
Barclays
17
Barclays
United Kingdom
$2.8M -$178K -8,536 -6%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$2.6M -$53.9K -2,584 -2%
Bank of America
19
Bank of America
North Carolina
$2.56M -$771K -36,931 -22%
ICM
20
Invenomic Capital Management
Massachusetts
$2.46M +$2.62M +125,562 New
BCM
21
Bridgeway Capital Management
Texas
$2.42M -$800K -38,321 -24%
Deutsche Bank
22
Deutsche Bank
Germany
$2.37M +$552K +26,463 +28%
TG
23
TCW Group
California
$2.36M +$73.1K +3,500 +3%
Principal Financial Group
24
Principal Financial Group
Iowa
$1.97M -$90.8K -4,347 -4%
Goldman Sachs
25
Goldman Sachs
New York
$1.94M +$317K +15,207 +18%

FLGT Hedge Fund Activity: Q2 2024 in Review

173 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q2 2024, worth a combined $299M — down 7.1% from $322M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of FLGT and 30 opened new positions — a net loss of 5 holders — while 48 trimmed existing stakes and 58 added.

The largest buyer was Millennium Management, adding an estimated $5.11M. The largest seller was Nuveen, cutting an estimated $3.58M.

  • 173 institutional investors held Fulgent Genetics (FLGT) as of Q2 2024, down from 180 in Q1 2024.
  • Funds reported $299M of Fulgent Genetics stock for Q2 2024, down 7.1% quarter-over-quarter.
  • 30 funds opened new Fulgent Genetics positions in Q2 2024 and 35 closed out, a net change of -5 holders.
  • The largest Fulgent Genetics buyer in Q2 2024 was Millennium Management, an estimated $5.11M added.
  • The largest Fulgent Genetics seller in Q2 2024 was Nuveen, an estimated $3.58M sold.

Based on aggregated 13F filings for Q2 2024.